Christopher J. Webster

An Efficient Development Paradigm for Biosimilars

G. Woollett, Christopher J Webster, Anny C Wong, 2019, BioDrugs.

Can there be abbreviated applications, generics, or follow-on products?

John Landis, A. Lubiniecki, G. Woollett, 2003 .

Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance

G. Woollett, Christopher J Webster, Kelly L George, 2021, BioDrugs.

A ‘Global Reference’ Comparator for Biosimilar Development

G. Woollett, Christopher J. Webster, 2017, BioDrugs.

Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”

G. Woollett, Christopher J. Webster, 2019, BioDrugs.

Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”

G. Woollett, Christopher J. Webster, 2018, BioDrugs.